Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

US FDA gives green light for use of AstraZeneca's Voydeya

(Sharecast News) - America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH). PNH is a condition under which some patients' immune systems destroy a larger proportion of red blood cells than they should, whilst EVH is the condition in which red blood cells outside of blood vessels were destroyed.

Voydeya could now be used as an add-on therapy to ravulizumab or eculizumab to treat EVH in adults with PNH.

The drug was a first-in-class, oral, Factor D inhibitor meant to address the needs of the roughly 10-20% of patients with PNH experiencing "clinically significant" EVH when they were being treated with a C5 inhibitor.

Share this article

Related Sharecast Articles

Frontier IP's Alusid launches another range with Topps Tiles
(Sharecast News) - Frontier IP announced on Friday that its portfolio company Alusid has launched its first range of floor tiles through Parkside Architectural Tiles, the commercial division of Topps Tiles.
Enteq appoints new head of finance
(Sharecast News) - Energy service engineering and technology company Enteq announced the appointment of Amir Absoud as its head of finance on Friday, to immediately succeed the current chief financial officer, Mark Ritchie.
EnSilica to raise £0.3m through retail offer
(Sharecast News) - EnSilica announced a retail offer through the Winterflood Retail Access Platform (WRAP) on Friday, to raise up to £0.3m.
Recurring revenue, adjusted earnings rise for Pulsar Group
(Sharecast News) - Audience intelligence software specialist Pulsar Group said in its final results on Friday that its annualised recurring revenue (ARR) increased £2.7m, a significant improvement from the flat performance in the prior financial year.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.